Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1021 to 1035 of 1251 results for public health guidance

  1. Inebilizumab for treating immunoglobulin G4-related disease [ID6600]

    In development Reference number: GID-TA11665 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]

    In development Reference number: GID-TA11880 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

    Technology appraisal guidance
    Discontinued

  4. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

    Technology appraisal guidance
    Discontinued

  5. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued Reference number: GID-TA11000

    Technology appraisal guidance
    Discontinued

  6. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued Reference number: GID-TA11026

    Technology appraisal guidance
    Discontinued

  7. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued Reference number: GID-TA10363

    Technology appraisal guidance
    Discontinued

  8. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]

    In development Reference number: GID-TA11457 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Emphysema - inhaled alpha-1 antitrypsin [ID1200]

    Discontinued Reference number: GID-TA11179

    Technology appraisal guidance
    Discontinued

  10. Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]

    In development Reference number: GID-TA11745 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    In development Reference number: GID-TA11491 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    In development Reference number: GID-TA11406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  14. Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]

    In development Reference number: GID-TA11792 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Deucravacitinib for treating active psoriatic arthritis [ID6561]

    In development Reference number: GID-TA11510 Expected publication date: TBC

    Technology appraisal guidance
    In development